If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
194
results.
Updated on
05/11/2025 [06:53:00]
Results 50 to 75 of 194
Absstract of: JP2025098004A
To provide methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC).SOLUTION: The present invention provides a method comprising administering to the patient an agonist of the Macrophage Stimulating 1 (MST1)/Macrophage Stimulating 1 Receptor (MST1R) pathway.SELECTED DRAWING: None
Absstract of: WO2025224462A1
The invention relates to DNA methylation and gene expression signatures for assessing the severity of IBD in a patient, monitoring the progression of IBD in a patient, and/or determining the efficacy of a therapeutic agent for treating IBD in a patient. The DNA methylation and gene expression signatures of the invention can also be used for the differential diagnosis of Crohn's Disease or Ulcerative Colitis in a patient having or suspected of having IBD. The invention further relates to intestinal epithelial organoids (IEOs) for predicting the efficacy of therapeutic agents and for screening agents for use in treating IBD. The invention further relates to therapeutic agents for use in treating IBD.
Absstract of: US2025332230A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Absstract of: US2025334593A1
In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
Absstract of: WO2025226885A1
The present invention relates to a biomarker associated with intestinal inflammation, and more particularly, to methods for diagnosing or identifying a risk of developing intestinal inflammation using mitochondrial DNA and methods of treating disorders associated with intestinal inflammation.
Absstract of: WO2024130444A1
The present application provides compositions and methods of use for inhibiting DUPD1 activity or by reducing or eliminating expression of DUPD1 in order to treat and/or prevent inflammatory bowel disease, including Crohn's disease and ulcerative colitis, colitis- associated colon cancer, or a metabolic disorder, such as obesity or an obesity-associated metabolic disorder, or for glucose regulation in a subject. The present application further relates to the identification of compounds that are useful in treating and/or preventing inflammatory bowel disease, colitis-associated colon cancer, or a metabolic disorder, or for glucose regulation.
Absstract of: WO2025218823A2
Disclosed in the present invention are a joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit of the present invention can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.
Absstract of: US2025319052A1
This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.
Absstract of: US2025321218A1
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.
Absstract of: EP4632080A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Absstract of: KR20250148382A
본 발명은 염증성 장질환(inflammatory bowel disease, IBD) 진단 및 치료를 위한 miRNA 바이오마커를 제공한다. 본 발명의 일 실시예에 따른 바이오마커는 염증성 장질환 진단용 조성물, 진단을 위한 정보 제공 방법, 염증성 장질환 예방 또는 치료용 약학 조성물, 염증성 장질환을 치료하는 방법 및 염증성 장질환 치료제의 스크리닝 방법에 활용될 수 있다.
Absstract of: WO2025210486A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Absstract of: US2025313880A1
Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Absstract of: US2025313613A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Absstract of: WO2025202626A1
The present techniques relate to a breath analysis device and a system for using such a breath analysis device. We also describe a method for using the breath analysis device. The breath analysis device comprises a filtering mechanism (which may also be termed a filter stack) for removing interferent chemicals to increase the accuracy of detection, identification and quantification of specific chemicals. Exhaled human breath comprises a multiplicity of vapour phase chemicals and the function of the filtering mechanism is removal, retardation and separation of chemicals other than the specific chemicals to be determined by the sensing element(s). Removal, retardation and separation of the chemicals other than those of interest reduces error by reducing cross sensitivities when using broadly selective sensors such as metal oxide semiconductors. One example use of the breath analysis device may be to enable users who suffer from digestive health problems, particularly irritable bowel syndrome (IBS) or small intestinal bacterial overgrowth (SIBO), to monitor symptoms based on detection of specific chemicals such as hydrogen and/or methane in their breath over time.
Absstract of: WO2025206567A1
The present invention provides a miRNA biomarker for diagnosing and treating inflammatory bowel disease (IBD). A biomarker according to one embodiment of the present invention can be utilized in a composition for diagnosing inflammatory bowel disease, a method for providing information for diagnosis, a pharmaceutical composition for preventing or treating inflammatory bowel disease, and a method for treating inflammatory bowel disease.
Absstract of: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Absstract of: US2025305068A1
The present invention relates to a new biomarker of inflammatory bowel disease and its uses. The new biomarker is a ratio of Dialister spp. to Phascolarctobacterium spp. This biomarker can be used for diagnosis purpose of diseases or disorders associated with an intestinal dysbiosis, for stratifying patient population in a clinical trial, for selecting a subject that will benefit from a treatment, or for monitoring treatment response. The present invention further provides new therapeutic strategies.
Absstract of: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Absstract of: US2025302891A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Absstract of: WO2025199410A1
The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.
Absstract of: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: US2025290143A1
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
Absstract of: WO2025193919A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Nº publicación: KR20250135709A 15/09/2025
Applicant:
연세대학교산학협력단
Absstract of: KR20250135709A
본 발명은 장 질환 예방 또는 치료용 조성물 및 장 질환 진단을 위한 정보제공방법에 관한 것으로, 인간의 장내 마이크로바이옴 분석을 통해 장 질환과 관련있는 유효 균주를 선별하였으며, 이들 중 크론병 등 장 질환에 치료 효과가 있는 균주를 확인하였는 바, 질병 진단 또는 장 질환의 예방, 개선 및 치료에 유용하게 활용될 수 있다.
BOPI
Electronic site
